192 related articles for article (PubMed ID: 11740817)
21. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood.
Shannon EJ; Ejigu M; Haile-Mariam HS; Berhan TY; Tasesse G
Lepr Rev; 1992 Mar; 63(1):5-11. PubMed ID: 1569817
[TBL] [Abstract][Full Text] [Related]
22. The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
Strupp C; Germing U; Aivado M; Kündgen A; Fenk R; Hünerlitürkoglu A; Kobbe G; Haas R; Gattermann N
Leuk Lymphoma; 2005 Jul; 46(7):999-1006. PubMed ID: 16019550
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide: an antineoplastic agent.
Amato RJ
Curr Oncol Rep; 2002 Jan; 4(1):56-62. PubMed ID: 11734114
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
25. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.
Bolomsky A; Schreder M; Meißner T; Hose D; Ludwig H; Pfeifer S; Zojer N
Exp Hematol; 2014 Jul; 42(7):516-25. PubMed ID: 24704163
[TBL] [Abstract][Full Text] [Related]
27. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
28. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC
Blood; 2002 Jun; 99(12):4525-30. PubMed ID: 12036884
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory assays to study structure-activity relationships of thalidomide.
Shannon EJ; Morales MJ; Sandoval F
Immunopharmacology; 1997 Jan; 35(3):203-12. PubMed ID: 9043933
[TBL] [Abstract][Full Text] [Related]
30. A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma.
Mercurio A; Adriani G; Catalano A; Carocci A; Rao L; Lentini G; Cavalluzzi MM; Franchini C; Vacca A; Corbo F
Curr Med Chem; 2017; 24(25):2736-2744. PubMed ID: 28571559
[TBL] [Abstract][Full Text] [Related]
31. Thalidomide: new indications?
Combe B
Joint Bone Spine; 2001 Dec; 68(6):582-7. PubMed ID: 11809002
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide and immunomodulatory drugs as cancer therapy.
Raje N; Anderson KC
Curr Opin Oncol; 2002 Nov; 14(6):635-40. PubMed ID: 12409654
[TBL] [Abstract][Full Text] [Related]
33. [Positive immunoregulation of thalidomide on human peripheral blood mononuclear cell cultures].
Yang Y; Zhang WG; Chen YX; Cao XM; He AL; Yang HY; Tian W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1172-7. PubMed ID: 17204188
[TBL] [Abstract][Full Text] [Related]
34. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide for erythema nodosum leprosum and other applications.
Okafor MC
Pharmacotherapy; 2003 Apr; 23(4):481-93. PubMed ID: 12680478
[TBL] [Abstract][Full Text] [Related]
36. Effects of immunomodulatory derivatives of thalidomide (IMiDs) and their analogs on cell-differentiation, cyclooxygenase activity and angiogenesis.
Fujimoto H; Noguchi T; Kobayashi H; Miyachi H; Hashimoto Y
Chem Pharm Bull (Tokyo); 2006 Jun; 54(6):855-60. PubMed ID: 16755058
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat.
Fernández-Martínez E; Morales-Ríos MS; Pérez-Alvarez V; Muriel P
Biochem Pharmacol; 2004 Oct; 68(7):1321-9. PubMed ID: 15345321
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC
Leukemia; 2003 Jan; 17(1):41-4. PubMed ID: 12529658
[TBL] [Abstract][Full Text] [Related]
39. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
40. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
Ribatti D; Vacca A
Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
